Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival (PFS) a 12 months from the enrollment higher than 30% for the patients submitted to allogeneic stem cell transplantation in front of the patients who received conventional chemotherapy.
12 months from the enrollement
Yes
Arcangelo Prete, MD, PhD, PI
Principal Investigator
S. Orsola-Malpighi Hospital
Italy: Ethics Committee
CE_clin.42_2009_S_sper
NCT00998361
June 2009
June 2011
Name | Location |
---|